A randomized controlled prospective study to assess the role of subconjunctival bevacizumab in primary pterygium surgery in Indian patients
Background: Pterygium is an ocular surface disorder with prevalence rates ranges from 0.3% to 29% in different parts of the world. Vascular endothelial growth factor (VEGF) has been detected in increased amounts in pterygium epithelium, compared with normal conjunctiva. Bevacizumab is a recombinant,...
Main Authors: | Priyanka Singh, Lopa Sarkar, H S Sethi, V S Gupta |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2015-01-01
|
Series: | Indian Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2015;volume=63;issue=10;spage=779;epage=784;aulast=Singh |
Similar Items
-
Subconjunctival Bevacizumab for Primary Pterygium Excision; a Randomized Clinical Trial
by: Mohammad-Reza Razeghinejad, et al.
Published: (2014-01-01) -
Subconjunctival Bevacizumab Injection in Treatment of Pterygium
by: Mohammad Reza Besharati, et al.
Published: (2011-03-01) -
Subconjunctival Bevacizumab Injection in Treatment of Pterygium
by: Mohammad Reza Besharati, et al.
Published: (2011-03-01) -
Subconjunctival bevacizumab injection versus mitomycin C application after primary pterygium surgery
by: Hani A Albialy, et al.
Published: (2019-01-01) -
Combined sutureless gluefree conjunctival autograft with subconjunctival bevacizumab for treatment of primary pterygium
by: Mona M Aly, et al.
Published: (2017-01-01)